ClinicalTrials.gg
CompletedNCT07892859Updated Oct 23, 2026

Liposomal Bupivacaine Fascia Iliaca Block for Perioperative Sleep Quality in Elderly Patients With Intertrochanteric Fracture

An interventional study of Liposomal Bupivicaine and Saline Solution (NaCl 0,9%) in Intertrochanteric Fractures, Hip Fractures and Sleep Disturbance, sponsored by Li Xiaoyuan. Completed at 1 site in China. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Li Xiaoyuan · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Oct 2026).
Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Study summary

Older adults with hip fracture often experience severe pain before and after surgery. This pain can cause anxiety and poor sleep, and may increase the risk of postoperative delirium (sudden confusion after surgery). A fascia iliaca compartment block (FICB) is an injection of numbing medicine near the hip nerves that relieves pain, but standard numbing medicines only last about 8 to 12 hours. Liposomal bupivacaine is a long-acting form of a numbing medicine that may relieve pain for up to 72 hours after a single injection.

This study tests whether giving an ultrasound-guided FICB with liposomal bupivacaine immediately after hospital admission (before surgery) improves sleep quality, reduces anxiety and pain, lowers the need for opioid pain medicines, and reduces postoperative delirium in patients aged 65 to 80 years undergoing surgery for intertrochanteric hip fracture, compared with a placebo (saline) injection. All participants in both groups receive the same standard pain treatment, including scheduled intravenous dexketoprofen and patient-controlled analgesia after surgery.

Read the detailed description

This is a prospective, randomized, placebo-controlled, double-blind, single-center trial. Eighty patients aged 65-80 years (ASA physical status II-III) scheduled for closed reduction and proximal femoral nail antirotation (PFNA) fixation of a unilateral intertrochanteric femoral fracture under intrathecal anesthesia are randomized 1:1 to two groups.

Immediately after enrollment on admission, the intervention group (Group Z) receives an ultrasound-guided suprainguinal fascia iliaca compartment block (FICB) with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline; the control group (Group D) receives 40 mL of normal saline by the identical technique. The block is performed by a single experienced anesthesiologist using a high-frequency linear probe and an in-plane technique, with the "hill sign" view (subcutaneous tissue, abdominal wall muscles, fascia iliaca, iliacus muscle, and ilium) confirming correct injection between the fascia iliaca and the iliacus muscle. Sensory blockade is assessed 20 minutes after injection by a blinded anesthesiologist using pinprick in the femoral, obturator, and lateral femoral cutaneous nerve territories; results are sealed and not used for clinical decisions until unblinding.

Both groups receive identical multimodal baseline analgesia (intravenous dexketoprofen trometamol 100 mg twice daily until the day of surgery), identical standardized spinal anesthesia (0.75% bupivacaine 1 mL diluted to 3 mL with cerebrospinal fluid at L3-4) with intraoperative dexmedetomidine infusion (0.3 microgram/kg/h), standardized hemodynamic management, and identical postoperative sufentanil-based patient-controlled intravenous analgesia (PCIA; sufentanil 1 microgram/kg in 150 mL, background 2 mL/h, bolus 2 mL, lockout 15 min). Rescue analgesia (intramuscular tramadol 50 mg) is given when resting VAS >= 4 despite PCIA.

Randomization is performed with an online random number generator (Research Randomizer) with allocation concealment using sealed opaque envelopes opened only by the study-drug preparation nurse, who does not participate in block performance, outcome assessment, or data analysis. Participants, the anesthesiologist performing the block, outcome assessors, and the statistician are blinded to group allocation.

The primary outcome is the Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission (the first night after the intervention). Secondary outcomes include LSEQ scores on the night of surgery and the second postoperative night, objective sleep parameters derived from a wrist-worn activity tracker (Fitbit Charge 6), anxiety scores, postoperative pain scores, perioperative sufentanil consumption, rescue analgesia, incidence of postoperative delirium (assessed twice daily on postoperative days 1-3 with the Confusion Assessment Method), time to first ambulation, postoperative length of stay, and adverse events.

The planned sample size of 40 per group provides 80% power (two-sided alpha = 0.05) to detect a between-group difference of approximately 34 points in the primary outcome assuming a pooled standard deviation of 52 points (based on an internal pilot study), allowing for 10% attrition.

02

Conditions studied

  • Intertrochanteric Fractures
  • Hip Fractures
  • Sleep Disturbance
  • Postoperative Delirium
  • Anxiety

Keywords

  • liposomal bupivacaine
  • fascia iliaca compartment block
  • preemptive analgesia
  • sleep quality
  • elderly
  • hip fracture
  • postoperative delirium
03

In context

Hip Fractures

848 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.

This study's enrollment of 80 is below the median of 90 across 540 interventional studies indexed under Hip Fractures.

Browse Hip Fractures studies →

Lead sponsor

This is the only study on the registry with Li Xiaoyuan as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Written informed consent signed by the patient or authorized legal representative 2. Unilateral intertrochanteric femoral fracture scheduled for closed reduction and PFNA internal fixation under intrathecal (neuraxial) anesthesia 3. Age 65-80 years, either sex 4. American Society of Anesthesiologists (ASA) physical status II-III 5. Body mass index 18-30 kg/m2

Exclusion criteria

Exclusion Criteria:

  • 1. Known allergy to lidocaine, bupivacaine, or liposomal bupivacaine 2. Trauma or infection at the puncture site, or coagulation disorder 3. Severe cardiac, pulmonary, hepatic, or renal insufficiency, or neurological disease 4. Severe cardiac arrhythmia 5. Long-term use or abuse of analgesic medications 6. Severe preoperative cognitive impairment precluding study assessments 7. History of psychiatric disorders (e.g., depression, anxiety disorder) 8. Pre-existing sleep disorder
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Experimental: Liposomal bupivacaine group (Group Z)

    Ultrasound-guided suprainguinal fascia iliaca compartment block with liposomal bupivacaine 133 mg diluted to 40 mL with normal saline, performed immediately after admission/enrollment.

    Drug: Liposomal Bupivicaine

  • Placebo comparator
    Placebo Comparator: Saline group (Group D)

    Ultrasound-guided suprainguinal fascia iliaca compartment block with 40 mL of 0.9% normal saline, performed immediately after admission/enrollment by the identical technique.

    Drug: Saline Solution (NaCl 0,9%)

Interventions

  • 1.Arm 1 - Experimental: Liposomal bupivacaine group (Group Z) * Intervention (Drug): Liposomal Bupivacaine * Description: Single ultrasound-guided suprainguinal FICB injection of liposomal bupivacaine 133 mg/10 mL diluted to 40 mL with 0.9% saline, injected between the fascia iliaca and iliacus muscle.

  • DrugSaline Solution (NaCl 0,9%)

    2.Arm 2 - Placebo Comparator: Saline group (Group D) * Intervention (Drug): Normal saline * Description: Single ultrasound-guided suprainguinal FICB injection of 40 mL 0.9% sodium chloride solution (placebo).

06

What researchers measure

Primary outcomes

  1. Leeds Sleep Evaluation Questionnaire (LSEQ) score on the night of admission

    Total LSEQ score (10 items, each scored on a 100-mm visual analogue line; total range 0-1000; higher scores indicate better sleep) for the night of admission, i.e., the first night after the study intervention, assessed the following morning by a blinded assessor.

    Time frame: Night of admission (within approximately 24 hours after the intervention)

Secondary outcomes

  1. LSEQ score on the night of surgery

    Time frame: Night of the day of surgery

  2. LSEQ score on the second postoperative night

    Time frame: Postoperative day 2 (night)

  3. Total sleep time (wristband actigraphy)

    Time frame: Objective total sleep time (hours) recorded by a wrist-worn activity tracker (Fitbit Charge 6). Time Frame: Night of admission, night of surgery, and second postoperative night

  4. Deep sleep time (wristband actigraphy)

    Time frame: Night of admission, night of surgery, and second postoperative night

  5. Number of nocturnal awakenings (wristband actigraphy)

    Time frame: Night of admission, night of surgery, and second postoperative night

  6. Anxiety score (VAS-A)

    Time frame: Night of admission, night of surgery, and second postoperative night

  7. Resting pain score (VAS)

    Time frame: 6, 24, and 48 hours after surgery

  8. Cumulative sufentanil consumption

    Time frame: 0-48 hours after surgery

  9. Number of effective PCIA demands

    Time frame: 0-48 hours after surgery

07

Study locations

1 site
  • Hebei Province Cangzhou Integrated Chinese and Western Medicine Hospital
    Cangzhou, Hebei 061000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Sep 2026, 8 months.

Of 225 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's 8 months is below that.

Counting every sponsor, half of 239 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2026
First posted
Oct 23, 2026
StartActual
Jan 1, 2026
Primary completionActual
Sep 1, 2026
CompletionActual
Sep 10, 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07892859
Lead sponsor
Li Xiaoyuan
Responsible party
Li Xiaoyuan (Attending physician, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine) — Sponsor-investigator
First posted
Oct 23, 2026
Start date
Jan 1, 2026
Primary completion
Sep 1, 2026
Completion
Sep 10, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion